TW200410712A - Anti-chicken coccidiosis composition - Google Patents
Anti-chicken coccidiosis composition Download PDFInfo
- Publication number
- TW200410712A TW200410712A TW092117674A TW92117674A TW200410712A TW 200410712 A TW200410712 A TW 200410712A TW 092117674 A TW092117674 A TW 092117674A TW 92117674 A TW92117674 A TW 92117674A TW 200410712 A TW200410712 A TW 200410712A
- Authority
- TW
- Taiwan
- Prior art keywords
- coccidiosis
- chicken
- antibody
- eimeria
- feed
- Prior art date
Links
- 208000003495 Coccidiosis Diseases 0.000 title claims abstract description 70
- 206010023076 Isosporiasis Diseases 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 241000287828 Gallus gallus Species 0.000 claims abstract description 59
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 50
- 241000894006 Bacteria Species 0.000 claims abstract description 31
- 239000004310 lactic acid Substances 0.000 claims abstract description 25
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 25
- 230000002163 immunogen Effects 0.000 claims abstract description 24
- 239000000427 antigen Substances 0.000 claims abstract description 18
- 102000036639 antigens Human genes 0.000 claims abstract description 18
- 108091007433 antigens Proteins 0.000 claims abstract description 18
- 239000012634 fragment Substances 0.000 claims abstract description 16
- 101710116435 Outer membrane protein Proteins 0.000 claims abstract description 12
- 210000003936 merozoite Anatomy 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims abstract description 9
- 210000003046 sporozoite Anatomy 0.000 claims abstract description 7
- 241000223924 Eimeria Species 0.000 claims description 28
- 235000013601 eggs Nutrition 0.000 claims description 22
- 241000271566 Aves Species 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 11
- 241000223932 Eimeria tenella Species 0.000 abstract description 20
- 230000000890 antigenic effect Effects 0.000 abstract description 3
- 241000193468 Clostridium perfringens Species 0.000 abstract description 2
- 241000223931 Eimeria acervulina Species 0.000 abstract 1
- 241000223934 Eimeria maxima Species 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 235000013330 chicken meat Nutrition 0.000 description 53
- 208000015181 infectious disease Diseases 0.000 description 22
- 235000019786 weight gain Nutrition 0.000 description 22
- 230000004584 weight gain Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- 230000003902 lesion Effects 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 230000003053 immunization Effects 0.000 description 14
- 238000002649 immunization Methods 0.000 description 14
- 210000003250 oocyst Anatomy 0.000 description 13
- 210000004534 cecum Anatomy 0.000 description 12
- 230000002320 anti-botulinal effect Effects 0.000 description 11
- 230000036039 immunity Effects 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 10
- 238000007689 inspection Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000003449 preventive effect Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000021050 feed intake Nutrition 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 241000224483 Coccidia Species 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 description 4
- 235000021053 average weight gain Nutrition 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000004215 spore Anatomy 0.000 description 4
- 208000016261 weight loss Diseases 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010016952 Food poisoning Diseases 0.000 description 3
- 208000019331 Foodborne disease Diseases 0.000 description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 210000000991 chicken egg Anatomy 0.000 description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 3
- 210000000287 oocyte Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 108030001720 Bontoxilysin Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000252983 Caecum Species 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229940053031 botulinum toxin Drugs 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000003224 coccidiostatic agent Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000007124 immune defense Effects 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 208000013435 necrotic lesion Diseases 0.000 description 2
- 210000002976 pectoralis muscle Anatomy 0.000 description 2
- -1 polyheptaine Proteins 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108010056594 Avian Proteins Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000770536 Bacillus thermophilus Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000289819 Eimeria adenoeides Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 241000238814 Orthoptera Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001165 anti-coccidial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000001563 schizont Anatomy 0.000 description 1
- 206010039766 scrub typhus Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Animal Husbandry (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
200410712 玖、發明說明: 【發明所屬之技術領域】 、,本發明係關於對雞球蟲病之預防及治療有效之組合物。 進-步具體言之,其係關於對雞等鳥類之㈣蟲病具優越 的預防效果及治療效果,對防禦雞球蟲病之感染及難球蟲 病伴有之體重下降之臨床症狀的改善,或雞球蟲病之治療 極為有效之組合物。 【先前技術】 雞球蟲病(coccidiosis in chickens)係由艾美球蟲(Eimeria) 屬之原蟲感染引起者。寄生於難之艾美球蟲屬,因種類不 同’其症狀、寄生部位、病變各異。特㈣,作為病原體 被重視者,有柔嫩艾美球蟲、毒害艾美球蟲、巨型艾美球 蟲、布氏艾美球蟲、堆型艾美球蟲5種,另外和緩艾美球蟲、 早熟艾美球蟲、哈氏艾美球蟲、變位艾美球蟲等亦為所知。 已知於鹤鶉域||艾美球蟲、E.ts刪dai等;於火雞為火雞 和緩艾美球蟲、E· adenoides、E· gall〇povonis等;於珠難 為由E. gremen、E· numidae等之感染所引起。此為雞的疾 病中,危害最大者之一。藉由卵囊之口服攝取可引起感染。 呈現各種腹瀉、食欲不振、絕嗣、體重下降等症狀,亦發 現有死亡。此與雞之日齡、性別、品種無關而發生。易發 生於地面放養之雞舍,但近年於多階梯式槽之採卵雞之發 生亦有報告。又,藉由肉毒杆菌(Clostridium perfringens)之 混合感染’症狀嚴重化。以防止卵囊引起之雞舍汗染及球 蟲預防劑之使用來對應。於預防上,可將各種合成抗雞球 86120 200410712 蟲劑及4才/ 7才予只抗生素作為球蟲預防劑使用。於治 療上,可使用磺胺藥物或磺胺藥物與嘧啶系藥物之合劑。 疫苗亦被實用化。 球蟲預防劑僅能於雞卵孵化後1 〇週内使用,另外具於離 難出貨前7曰之停藥期間之義務。此係因於用藥之情形,一 定期間内卵、肉之出貨被禁止。此球蟲預防劑不能使用之 期間内,雞球蟲病易發生。再者,因耐藥性雞球蟲增加, 有必要選擇對各農場有效之預防劑。雖然難球蟲病之球蟲 預防劑一時間開發出極多,但其後,因殘留、對包括人之 其他生物之惡性影響、耐藥性難球蟲之出現等,變為不能 使用。於歐洲,2007年以後,球蟲預防劑之使用被禁止。 於我國自對飼料添加物之法規實施以來,其使用亦被嚴重 限制。 活疫苗’為口服投與者,以病原性弱之種類進行計劃免 疫’從而防止強毒種之感染之嘴試正在進行。又,將數種 卵囊之混合物用於離’使其感染至不死亡之程度,從而使 其獲得免疫之難球蟲活疫苗,實際上因養雞場被汗染,不 如說負面點多。於非活化疫苗,阻止感染之抗體之產生少, 且效果亦低。又,即使用疫苗免疫離,因到防禦感染之抗 體產生為止需要數週,故於離雞之利用價值低。 另外’一旦患難球蟲病’腸内菌群紊,引起腹湾等症 狀,特別地,腹瀉涉及長期。又,由此體力消耗,免疫力 下降而導致易患壞死性腸炎。 使用特許第2548 11 5號、特許第2698778號、特許第2698779 86120 200410712 號(鳥抗體之哺乳動物之被動免疫化,於投與為被動免疫 之異種抗體(來自難卵)之際(特別地,注射等非口服投與), 為防止引起過敏性休克及血清病等,於投與為預防/治療 之抗體之前,預先給哺乳動物含有抗體之食物,使其置於 口服免疫耐义(免疫寬容)之狀態,與本發明之口服被動免疫 防禦效果之想法芫全相異。又,本發明者等,對關於食用 鳥之食物中毒菌抑制材料(特許第2615673號)提出申請。其 係以豬大腸杆菌症之原因之腸毒素原性大腸杆菌987ρ、κ88 及Κ99彡/l原,及牛大細杆菌症之原因之腸毒素原性大腸杆菌 Κ99抗原中任1種以上之抗原免疫雞,由此免疫雞產的卵至 少含有卵黃之部分回收抗體而獲得,含有對前述抗原之特 異性多克隆抗體,含有豬或牛之哺乳期之大腸杆菌症之口 服預防劑及治療劑(特許第2034005號),及預先接種食物中 毒菌之雞於免疫獲得後產生的卵之全卵、卵黃或含有抗體 之組分’其含有對該食物中毒菌之特異抗體。此等具雞卵 抗體之有用性,對細菌雖具雞卵抗體之口服被動免疫防禦 效果,但對原蟲並不顯示防禦效果。即使於今,雖有對細 ®或病毒等具口服被動免疫能力之想法,但並無對原蟲之 口服被動免疫能力之想法。 另’雖有多數對使用難球蟲病之各種抗原之疫苗的報告, 但使用被動免疫之報告為少。針對雞球蟲病之巨型艾美球 蟲的生殖母體製作小鼠單克隆抗體,雖有確認於雞球蟲病 之被動免疫的論文(Infection and Immunity,56: 972-976, 1988, Infection and Immunity, 58 : 557-562,1990),但其以 86120 200410712 將小鼠單仏抗體非口服而以靜脈注射之投與方法進行每 驗,完全無實用意義。 只 【發明内容】 本發明者等必要解決前述問題點,而銳意研究之結果, 1現藉由以具有參與雞球蟲病之堆型艾美球蟲、柔嫩 球蟲及巨型艾吴球蟲之孢子體與裂殖子之共同免疫原性之 外膜蛋白質抗原或其免疫原性片段作為抗原,免疫雞、鹌 鶴或其他鳥類獲得之㈣所含之抗雞球蟲病抗體投與雞等 鳥類’抗體附著於艾美球蟲屬之孢子體或裂殖子,藉由阻 止孢子m或裂殖子附著及侵入上皮細胞,可使其病原性消 失。再者,於投與本抗雞球蟲病抗體之際,藉由合併供給 乳酸菌,發現與腸内菌群之改善及免疫增強之同時,本= 體更有效地發揮作用’對難球蟲病之預防及治療可發揮^ 越的效果。又,於投與本抗雞球蟲病抗體之際,藉由合併 供給由以肉毒杆菌免疫過之難蛋得到之抗體,纟現藉由抑 制混合感染肉毒杆菌所致之症狀嚴重化,使本抗體更有效 地發揮作用’對雞球蟲病之預防及治療發揮優越的效果而 完成本發明。 本發明包含以下發明。 (1) 一種口服用抗雞球蟲病組合物,其包含一抗體,該 抗體係得自以具有參與難球蟲病之堆型艾美球蟲、柔嫩艾 美球蟲及巨型艾美球蟲之孢子體與裂殖子之共同免疫原性 之外膜蛋白質抗原或其免疫原性片段免疫之難蛋。 (2) 如前述(1)記載之組合物,其另含有乳酸菌。 86120 200410712 由以肉毒杆菌 (3) 如前述⑴或(2)記載之組合物,其另含有 免疫過之雞蛋獲得之抗體。 用於雞球蟲 (4) 如前述⑴-(3)之任—項記載之組合物,其 病之預防或治療。 項記載之 (5) —種鳥類用飼料,其含有前述(iH4)之任一 組合物。 士(6卜種難球蟲病之預防或治療方法,其特徵在於將前述⑴ 圮載《抗體’或該抗體與由乳酸菌及/或肉毒杆菌免疫過之 難蛋獲得之抗體口服投與給鳥類。 以下,茲詳細說明本發明。 本發明,作為抗原係使用參與難球蟲病之堆型艾美球蟲、 柔嫩艾美球蟲及巨型艾美球蟲之孢子體與裂殖子之共同免 疫原性之外膜蛋白質抗原或其免疫原性片段。 前述抗原,因係堆型艾美球蟲、柔嫩艾美球蟲及巨型艾 美球蟲之孢子體與裂殖子之纟同抗原、’於病原體為堆型艾 美球蟲、柔嫩艾美球蟲及巨型艾美球蟲任一種之情形均有 效發揮作用。 作為前述抗原,可使用例如Avian叫⑶%% 44:379_389 2000記載之18-27千道爾頓之可溶性蛋白(1?3)或3β1 E蛋白 質’ J· Parasitol·,84 ·· 654-656, 1998記載之千道爾頓之裂殖 1991記載之 子蛋白,Infection and Immunity, 59:1271-1277 防禦片段蛋白(FV)。 作為「免疫原性片段」,含有一個或其以上之免疫決定簇, 只要可作為免疫原使用者,無特別限定。 86120 -10- 200410712 抗體因有可識別3個氨基酸形成之氨基酸序列的報告(F. Hudecz et al.5 J. Immunol. Methods, 147: 201-210 (1992)) 作為前述免疫原性片段之最小單位,認為氨基酸殘基數為3 以上的肢鏈,可列舉為氨基酸殘基數5以上為佳,氨基酸殘 基數1 0以上之肚鍵或多肢更佳。 又,前述外膜蛋白質抗原或其免疫原性片段,亦可藉由 液相法及固相法等之肽鏈合成方法合成,進一步亦可使用 肚鏈自動合成裝置,可依據以下記載之方法合成··日本生 化學會編「生化學實驗講座i夕>八夕質(7)化學以」,東京 化學同人,1975年,泉屋等人「弋7。千卜、合成①基礎七實 驗」,丸善,1985年,曰本生化學會編「續生化學實驗講座 2夕化學下」,東京化學同人,198?年等。 再者,前述外膜蛋白質抗原或其免疫原性片段者,由含 有對應足鹼基序列之!)凡八或RNA使用基因工程學技術(例 如’參照日本生化學會編「續生化學實驗講座丨遣傳子研究 法I」,東京化學同人,1986年,曰本生化學會編「續生化 學實驗講座1遺傳子研究法n」,東京化學同人,1986年,曰 本生化學會編「續生化學實驗講座丨遺傳子研究法」,東 京化學同人,1987年)製作亦可。 W述免疫原性片段為低分子物質之情形,通常,使用讓 載體結合於該片段者。作為前述載體,可使用裂螺科之血 藍蛋白(KLH)、牛血清白蛋白(BSA)、人血清白蛋白(hsa)、 難血清白蛋白、多七離氨酸、多丙氨酸離氨酸、雙棕櫚酸 離氨酸、破傷風類毒素或多糖類等。前述免疫原性片段與 86120 200410712 載體之結合,可使用戊二醛法、1_乙烯基-3-(3-雙甲基氨两 基)碳二亞胺法、亞gS胺苯臨-N-輕基琥珀驢亞胺酯法、- 丨丨-¾ 重氮化聯苯胺、N-琥珀醯亞胺基-3-(2-吡啶基二硫代)丙酸 法等眾所週知之方法。又,亦可將前述免疫原性片段吸附 於硝化綿顆粒、聚乙烯吨洛酮、脂質體等之載體者作為免 疫原。 免疫方法,可使用免疫原(前述外膜蛋白質抗原或其免疫 原性片段)之皮下注射及筋肉内注射、口服投與等。作為蛋 白質或肽鏈,接種免疫原量為0.01_10mg為佳。藉由初次免 疫2-10週後進行加強免疫,可得到較高抗體效價。加強免 疫第2週以後,對雞球蟲抗原起特異性反應之抗體,不僅於 ’隹6血中,且於卵中亦有生成。如此免疫之抗體,通常 高抗體效價可維持4個月。即使於抗體效價下降之情形,只 要以同樣手法進行加強免疫,高抗體效價即可持續。此卵 之抗體活性,可藉由螢光抗體法或酵素抗體法測定。 前述免疫原’與佐劑;昆合免疫注射者為佳。作為佐劑, 可使用福氏完全佐劑、福氏不完全佐劑、氧化銘佐劑、百 日咳遠佐骑彳等眾所週知者。 所述得到切的抗體,可將全彡卩或彡卩黃製成溶液, 5猎由噴霧乾燥機等乾燥製成粉末使用,另外亦可由全卵 或^脫^ *用印水溶性蛋白質,進—步精製或粗精製 抗體使用。 本發明之組合物,;奋m、人& & 麵、 k用於鳥^,特別適用於難。前述抗 月亘足投與量,一般地, — 十$母天對母隻雞抗體效價為卜106 86120 -12 - 200410712 品種等適宜增減為佳。 么’但根據鳥類的週齡、性別 又’於投與前述抗體之際,—旦合併使用乳酸菌,雞球 ^病伴有之體重下降等症狀可進—步被改善。乳酸菌,通 一常可對於前述抗體1§以乳酸菌10_1〇9個之比例使用。乳酸 菌,可與前述抗體同時投與,間隔投與亦可。 f) 田:為於此被使用之乳酸菌,只要為屬於乳酸桿菌、雙叉 杯囷、鏈球菌、腸球菌、乳球菌等之屬之乳酸菌,不問其 2,早獨或混合多種株均可。作為屬於乳酸桿菌屬之乳酸 菌例如嗜酸乳桿菌、保加利亞乳桿菌、乾酪乳桿菌、乙· ntum、鼠李糖乳桿菌、L· paracasei、乳酸乳桿菌、胚 芽乳桿菌、囉伊氏乳桿菌、鼠李糖乳桿菌、唾液乳酸桿菌; 作為屬於雙又桿菌屬之乳酸菌,例如青春雙叉桿菌、分歧 雙叉扣菌、短雙叉桿菌、嬰兒雙歧桿菌、長雙叉桿菌、Β·
二eUd〇1〇ngUm、嗜熱雙叉桿菌;作為屬於鏈球菌屬之乳酸 菌,例如操乳鏈球菌、唾液鏈球菌、嗜熱性鏈球菌;作為 屬、;和求菌屬之乳酸菌,例如糞腸球菌、腸球菌;作為屬 於乳球菌屬之乳酸菌,例如乳酸乳球菌可被列舉。 又,於投與前述抗體之際,一旦合併使用由肉毒杆菌免 疫過(難蛋得到之抗體(以下稱為「抗肉毒杆菌抗體」),難 球蟲病伴有之體重減少等症狀可進一步改善。抗肉毒杆菌 杬把,通常對於抗雞球蟲病抗體lg可以0.01-100g之比例使 用。抗肉母杆菌抗體,可與前述抗難球蟲病抗體同時投與, 間隔投與亦可。 抗肉毒杆菌抗體,除作為免疫原使用肉毒杆菌以外,可 86120 -13 - 200410712 藉由與前述抗雞球蟲病抗體同樣的方法製作。又,藉由作 為免疫原將肉毒杆菌與前述外膜蛋白質抗原或其免疫原性 片段同時使用,亦可同時製作抗肉毒杆菌抗體及抗雞球蟲 病抗體。 作為肉毒杆菌’例如可將j· Anim· Sci·,75:19-25,1997記 載之蛋白、Avian Diseases,21: 241-255,1977 記載之類毒 素、Vet· Rec·,120: 435-439, 1987記載之蛋白、Vaccine,n: 1253-1258,1993 記載之蛋白、FEMS Immunol· Med.
Microbiol·,7: 321-336,1993記載之蛋白作為抗原使用。 本發明之抗難球蟲病組合物,作為各有效成分濃度為 0·001%-10%之溶液,甚至以粉末、顆粒、錠劑或膠狀對於 飼料以各有效成分濃度為〇·〇〇!%_!〇%之範圍被供給。又, 於供給抗雞球蟲病抗體之際,為防止於胃之消化分解,亦 可製成腸溶性劑形。 本發明說明,包括本申請優先權之基礎之特願2〇〇2_ 189 137號發明說明中記載之内容。 【實施方式】 〔實施例1〕 將難球蟲之堆型艾美球蟲ΝΑ株(ΡΕ0101)、柔嫩艾美球蟲 ΝΜ株(ΡΕ0102)、巨型艾美球蟲ΝΤ株(ΡΕ〇1〇3)之卵囊分別讓 4週齡的難以2χ106個口服感染,感染後第4日進行剖檢,得 到腸管及腸管内容物。各孢子體及裂殖子之精製,依據 Diseases,39:53 8-547,1995進行。藉由將堆型艾美球蟲na 株之裂殖子之可溶性外膜蛋白質於SDS-PAGE進行電泳,得 86120 -14- 200410712 到 18-27kD之外膜蛋白質(Avian Diseases,44 ·· 379-389, 2000)。將含此外膜蛋白質〇.5nig/mi之溶液與福氏不完全佐 劑乳化’給12週齡之雌難左右胸肌各注射1 mi進行第一次 免疫。同樣,6週後,同樣進行第二次免疫。第二次免疫2 週後’此雞之血液中之抗難球蟲病抗體於酵素免疫法分析 (ELISA)(Avian Diseases,44:379-389,2000)之抗體效價為 3 0,000-120,〇〇〇倍。此雞產的卵之抗體效價為3〇,〇〇〇-12〇,〇〇〇 倍。此抗體效價持續4個月。收集此卵,藉由喷霧乾燥製成 全印粉末之雞卵抗體。此粉末之抗體效價為6〇,〇〇〇倍。又, 將對於本抗體之孢子體及裂殖子之相交性以間接免疫熒光 染色(Avian Diseases,44:379-389,2000)研究之結果,本抗 體將艾美球蟲屬堆型艾美球蟲、柔嫩艾美球蟲、巨型艾美 球蟲之孢子體及裂殖子表面特異性熒光染色,確認其係共 通抗體。 〔實施例2〕 將於貝施例1仔到之抗難球蟲病抗體添加至離雞飼料中, 研九其對雞球蟲病實驗感染難(柔嫩艾美球蟲 Disease,3 1: 112-119, 1987)之效果,供試驗動物採用離雞專 用種強難(chunky),抗體以〇·1。/。,1%及1〇%添加至雛雞育肥 前期用標準飼料(SDB Νο·1:Β團法人畜產生物安全研究所) 後投與。柔嫩艾美球蟲ΕΤ株之卵囊感染為1〇〇〇個/隻 Protozool,9: 154_161,1962),每組按比例各設定1〇隻。又, 感染後之觀察期間為2週。檢查項目,以體重增加量及飼料 要求率為主要檢查項目,其他實施〇·Ρ (}•(平均每克糞便之 86120 -15- 200410712 卵囊數)及盲腸病變觀察(角田清監修「雞口夕シ^々A症」、 千夕寸 > 出版社、1983年)。其結果,藉由體重增加量,於 0.1 %投與組其效果亦被確認,藉由飼料要求率於1.0%投與 組其效果被確認。 综上,針對難球蟲病之攻擊,藉由將抗難球蟲病抗體以 0.1%以上投與於飼料中,發現有包含體重增加量及飼料要 求率之改善。综合判定,以得到之各觀察項目之數值為基 礎判定被檢物之效果,得到極為有效之效果。 表1 非感染組 柔嫩艾美球蟲感染組 非添加組 於飼料Θ 17添加之; :元體之比例 0% 0% 0.1% 1% 10% 平均體重增加量(g) 731 578 622 620 666 相對體重增加率(%)a) 100 79 85 85 91 平均飼料攝取量(g) 879 885 910 862 915 飼料要求率b) 1.20 1.53 1.46 1.39 1.37 生存率(%) 100 100 100 100 100 OPG(xl04)第 7 曰 0.0 9.7 5.1 4.2 0.4 卵囊值e) 0 40 20 10 5 盲腸病變值d) 0 20 10 5 5 Acmc) 200 119 155 170 181 稍有效 中度有效 極有效 a):相對體重增加率(%) =感染組體重增加率+非感染組體重 增加率X 1 〇 0 86120 -16- 200410712 b)·飼料要求率=平均飼料攝取量+平肖體重增加量 C)藉由相對於對照組之o.p.g·之比例=用藥組之〇.P G々感 染無用藥組之aRG· χ⑽’以基準為基礎,求出各試驗二 《卵囊值。〇 : 〇]%,+5 : 1.1-25%,+1〇 : 26_5〇%,+2〇 : 51-75〇/〇,+4〇 : 76]〇〇%。 )目腸病4值,依據〇 :未發現病變;+1 :盲腸壁上散在 有:少數點狀出血斑,但内容物正常;+2:内容物中混有 y :血液’可見多數出血病竈;+3 :可明顯見到盲腸内含 有夕里血液,或盲腸核(凝血或灰白色奶酪狀,香蕉型塊狀), 目腸壁肥厚’及盲腸之變形、萎縮。+4 :盲腸嚴重萎縮, 病變到達直腸部。壁極度肥厚,盲腸内含有凝血或盲腸核; <判足基準求出1隻之平均值,換算成10隻的值示於表!。 幻:ACI值(Anticoccidial Index:抗雞球蟲指數)气相對體重 增加率+生存率)-(卵囊值+病變值) ACI值:18〇以上…極有效,16〇_179…中度有效, 稍有效’不足12 0…無效。 〔實施例3〕 使用將實施例1中得到之抗雞球蟲病抗體與乳酸菌之嗜酸 乳杆菌混合之飼料,研究對雞球蟲實驗感染雞(柔嫩艾美球 蟲)之效果。乳酸菌之嗜酸乳杆菌ATCC4356株於MRS培基 培養後,藉由凍乾製成lxl〇1H@/g的粉末。供試驗動物採用 離雞專用種強雞chunky,向離雞育肥前期用標準飼料(sdb No. 1)添加前述抗體〇· 1 %與乳酸菌1 〇6個/g投與。柔嫩艾美球 蟲ET株之卵囊感染為1000個/隻,每組按比例各設定1〇隻。 86120 -17- 200410712 又,感染後之觀察期間為2週,檢查項目,以體重增加量及 飼料要求率為主要檢查項目,其他實施O.P.G.及盲腸病變觀 察。其結果,藉由體重增加量,於抗體與乳酸菌之投與組 其效果被確認,藉由飼料要求率其效果亦被確認。 综上,針對難球蟲病之攻擊,藉由將抗雞球蟲病抗體與 乳酸菌之嗜酸乳桿菌投與於飼料中,發現有包含體重增加 量及飼料要求率之改善。综合判定,以得到之各觀察項目 之數值為基礎判定被檢物之效果,發現極為有效之效果。 表2 非感染組 柔嫩艾美球蟲感染組 非添加組 添加於飼料 對照組 對照組 抗體0.1% 抗體+乳酸菌 平均體重增加量(g) 731 578 622 666 相對體重增加率(%) 100 79 85 91 平均飼料攝取量(g) 879 885 910 845 飼料要求率 1.20 1.53 1.46 1.27 生存率(%) 100 100 100 100 OPG(xl04)第7 曰 0.0 9.7 5.1 2.2 卵囊值 0 40 20 5 盲腸病變值 0 20 10 5 ACI值 200 119 155 181 稍有效 極有效 〔實施例4〕 使用將實施例1中得到之抗難球蟲病抗體與由肉毒杆菌免 86120 -18- 200410712 疫過之雞蛋得到之抗肉毒杆菌抗體混合之飼料,研究其對 雞球蟲病(柔嫩艾美球蟲)與肉毒杆菌之混合感染實驗雞 (Avian Disease,24 : 324-333,1980)之效果。 抗肉毒杆菌抗體,係將肉毒杆菌ATCC3624株於巯基乙醇 酸鋼培基培養,將含此1 x 101G個/ml之菌液與福氏不完全佐 劑乳化,給12週齡之雌難左右胸肌各注射1 ml,進行第一 次免疫。同樣,6週後,同樣進行第二次免疫。第二次免疫 2週後,此雞之血液中之抗肉毒杆菌抗體藉由菌體凝集法測 定之抗體效價為300-1200倍。此難產的卵之抗體效價為300-1200倍。此抗體效價持續4個月。收集此卵,藉由噴霧乾燥 製成全卵粉末之雞卵抗體。此粉末之抗體效價為600倍。 供試驗動物採用離難專用種強雞(chunky),向離雞育肥前 期用標準飼料(SDB No. 1)添加抗雞球蟲病抗體0.1 %與抗肉 毒杆菌抗體0.1 %,投與。柔嫩艾美球蟲ET株之卵囊感染為 1000個/隻,肉毒杆菌ATCC3624株為107個/隻,每組按比例 各設定10隻。又,感染後之觀察期間為2週,檢查項目,以 體重增加量及飼料要求率為主要檢查項目,其他實施O.P.G. 及盲腸病變觀察。其結果,藉由體重增加量,於抗雞球蟲 抗體與抗肉毒杆菌抗體之混合投與組其效果被確認,藉由 飼料要求率其效果亦被確認。 综上,針對難球蟲病與肉毒杆菌之混合攻擊,藉由將抗 雞球蟲病抗體0.1 %與抗肉毒杆菌抗體0.1 %與飼料合併使用 投與,發現有包含體重增加量及飼料要求率之改善。综合 判定,以得到之各觀察項目之數值為基礎判定被檢物之效 86120 -19- 200410712 果,發現極為有效之效果。 表3 非感染組 柔嫩艾美球蟲+肉毒杆菌感染組 非添加組 添加於飼料 對照組 對照組 難球蟲 病抗體 0.1% 雞球蟲病抗體 0.1%+肉毒杆菌 抗體0.1% 平均體重增加量(g) 731 563 620 629 相對體重增加率(%) 100 77 85 86 平均飼料攝取量(g) 879 880 905 865 飼料要求率 1,20 1.56 1.46 1.38 生存率(%) 100 100 100 100 OPG(xl04)第 7 曰 0.0 12.0 6.3 0.1 卵囊值 0 40 20 0 盲腸病變值 0 24 12 3 ACM 200 113 153 183 稍有效 極有效 〔實施例5〕 將於實施例1得到之抗雞球蟲病抗體添加至飼料中,研究 其對雞球蟲病實驗感染難(堆型艾美球蟲)(Avian Disease,3 1: 112-119,1987)之效果。供試驗動物採用離難專用種強雞 (chunky),抗體以0.1%、1%及10%添加至離難育肥前期用 標準飼料(SDB No. 1)後投與。堆型艾美球蟲EA株之卵囊感 染為1000個/隻,每組按比例各設定10隻。又,感染後之觀 86120 -20- 200410712 察期間為2週,檢查項目,以體重增加量及飼料要求率為主 要檢查項目,其他實施O.P.G.及小腸病變觀察。其結果,於 〇.1 %投與組其效果亦被確認。 综上,針對雞球蟲病之攻擊,藉由將抗難球蟲病抗體以 0.1%以上投與於飼料中,發現體重增加量之改善。 表4 非感染組 堆型艾美球蟲感染組 非添加組 於飼料c 卜添加之抗體之比例 0% 0% 0.1% 1% 10% 平均體重增加量(g) 731 580 630 650 680 相對體重增加率(%) 100 79 86 89 93 平均飼料攝取量(g) 879 826 869 845 820 飼料要求率 1.20 1.4 1.38 1.30 1.22 生存率(%) 100 100 100 100 100 OPG(xl04)第 7 曰 0.0 5.0 4.5 4.0 0.3 卵囊值 0 40 40 40 5 小腸病變值a) 0 20 5 5 0 ACM 200 119 141 144 188 稍有效 稍有效 極有效 a):小腸病變值,依據0 :未發現病變;+1 :十二指腸可見 散在有含有卵囊之白色壞死病竈;+2:白色壞死病竈數增 加,且病竈延長至小腸上部;+3 :病竈增加,融合。小腸 壁肥厚,内容物為水樣;+4 :因多數病竈互相融合,十二 指腸及小腸上部呈現灰色。壁高度肥厚,内部含有奶油狀 86120 -21 - 200410712 黏液;之判定標準,求出1隻之平均值,換算成1〇隻的值示 於表4。 只訑例2 3及5,將抗雞球蟲病抗體、或該抗體與乳酸 菌此口於飼料,對雞連續供給時,發現其使實驗感染雞球 蟲病者發病減輕,出現體重增加之效果。又,對感染雞球 蟲病之雞,將柷雞球蟲病抗體與乳酸菌混合於飼料,供給 <時’其症狀明顯改善,發現包括體重增加量及飼料要求 率 < 改善。又,合併使用抗肉毒杆菌抗體,預防難球蟲病 之發病,發現包括體重增加量及飼料要求率之改善。 本發明說明中引用之全部刊物,特許及特許申請,均保 持原樣作為參考放入本發明說明中。 屋業上利用之可能性 本發明中包含抗雞球蟲病抗體與乳酸菌或抗肉毒杆菌抗 眼之抗雞球蟲病組合物,因對雞球蟲病特異性起作用,替 代抗雞球蟲劑或疫苗,對難球蟲病發揮出極為有效之預防 效果之同時,對雞球蟲病之症狀減輕及體重增加極為有效 地起作用。 86120 22-
Claims (1)
- 200410712 拾、申請專利範園: 1 · 一種口服用抗雞球蟲病組合物,其包含一抗體,該抗體係 得自以具參與雞球蟲病之堆型艾美球蟲、柔嫩艾美球蟲及 巨型艾美球蟲之孢子體與裂殖子之共同免疫原性之外膜蛋 白質抗原或其免疫原性片段免疫之雞蛋。 2·如申請專利範圍第丨項之口服用抗雞球蟲病組合物,其另 含有乳酸菌。 3·如申請專利範圍第1項之口服用抗雞球蟲病組合物,其另 含有以肉毒杆菌免疫過之雞蛋得到之抗體。 4·如申請專利範圍第丨項之口服用抗雞球蟲病組合物,其用 於雞球蟲病之預防或治療者。 〃 5. —種鳥類用飼料,其係、包含如申請專利範圍第p 物者。 β 口 86120 200410712 柒、指定代表圖: (一) 本案指定代表圖為:第(無)圖。 (二) 本代表圖之元件代表符號簡單說明: (無元件代表符號) 捌、本案若有化學式時,請揭示最能顯示發明特徵的化學式: 86120
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002189137A JP3995541B2 (ja) | 2002-06-28 | 2002-06-28 | 抗鶏コクシジウム症組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200410712A true TW200410712A (en) | 2004-07-01 |
Family
ID=29996838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092117674A TW200410712A (en) | 2002-06-28 | 2003-06-27 | Anti-chicken coccidiosis composition |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20060057150A1 (zh) |
| EP (1) | EP1552848B1 (zh) |
| JP (1) | JP3995541B2 (zh) |
| KR (1) | KR100617415B1 (zh) |
| CN (1) | CN1678349A (zh) |
| AT (1) | ATE411816T1 (zh) |
| AU (1) | AU2003243999A1 (zh) |
| DE (1) | DE60324299D1 (zh) |
| TW (1) | TW200410712A (zh) |
| WO (1) | WO2004002527A1 (zh) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004189672A (ja) * | 2002-12-11 | 2004-07-08 | Gen Corp:Kk | 抗下痢症組成物 |
| US8110188B2 (en) * | 2003-03-18 | 2012-02-07 | Investigacion Aplicada, S.A. De C.V. | Compositions for prevention and treatment of infections caused by coccidia in chickens |
| JP2006036661A (ja) * | 2004-07-23 | 2006-02-09 | Gen Corp:Kk | 歯周炎を治療又は予防するための組成物 |
| US8877187B2 (en) | 2005-07-25 | 2014-11-04 | Avianax, Llc | Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases |
| AU2006285306B2 (en) | 2005-07-25 | 2012-07-19 | Avianax, Llc. | Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases |
| RU2561673C2 (ru) * | 2006-03-30 | 2015-08-27 | Эмбрекс, Инк. | Способы и композиции для вакцинации домашней птицы |
| CN101186647B (zh) * | 2007-12-13 | 2010-04-21 | 成都乾坤动物药业有限公司 | 鸡球虫高免卵黄抗体的制备方法 |
| JP2011016843A (ja) * | 2010-10-13 | 2011-01-27 | Gen Corp:Kk | 歯周炎を治療又は予防するための組成物 |
| WO2014022572A1 (en) * | 2012-08-01 | 2014-02-06 | Pacific Vet Group-Usa, Inc. | Probiotic for amelioration of coccidiosis vaccine reaction |
| TWI463987B (zh) * | 2012-09-17 | 2014-12-11 | Univ Hungkuang | 使用包含有4株乳酸菌菌株的混合物來預防和/或治療雞球蟲病 |
| CN103554046B (zh) * | 2013-11-08 | 2015-04-01 | 中国农业科学院上海兽医研究所 | 一种具有抗鸡球虫病的三嗪化合物 |
| PL3145522T3 (pl) * | 2014-05-23 | 2021-06-14 | Phibro Animal Health Corporation | Kombinacja, kompozycja i sposób podawania kombinacji lub kompozycji zwierzętom |
| AR103086A1 (es) * | 2014-12-17 | 2017-04-12 | Nutrition Physiology Company Llc | Composiciones y métodos para reducir las infecciones en aves de corral |
| WO2018131930A1 (ko) * | 2017-01-12 | 2018-07-19 | 차장옥 | 콕시듐증 예방 또는 치료용 조성물, 이의 제조방법 및 이의 이용 |
| MX2019009554A (es) * | 2017-02-13 | 2020-01-30 | Us Agriculture | Producto de huevo hiperinmunizado para el tratamiento de enteritis necrotica en aves de corral. |
| CN108553640A (zh) * | 2018-06-13 | 2018-09-21 | 佛山市正典生物技术有限公司 | 一种鸡球虫病弱毒活疫苗及其制备方法和应用 |
| US11497197B2 (en) * | 2018-07-18 | 2022-11-15 | University Of Connecticut | Methods for enhancing poultry growth and performance |
| BE1028700B1 (nl) * | 2020-10-13 | 2022-05-16 | Poulpharm Bvba | Werkwijze voor het testen van de efficiëntie van anti-parasitaire (coccidiose) middelen bij pluimvee en konijnen |
| CN115105518B (zh) * | 2022-06-30 | 2023-08-18 | 广东省农业科学院作物研究所 | 马先蒿苷a在制备鸡饲料或者抗鸡球虫病的药物中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0135073A3 (en) * | 1983-08-19 | 1987-05-27 | American Cyanamid Company | Antigens and monoclonal antibodies reactive against merozites of eimeria spp. |
| CA1340520C (en) * | 1984-06-05 | 1999-05-04 | Karel Z. Newman Jr. | Antigenic proteins and vaccines containing them and protective antibodies directed to them for prevention of coccidiosis caused by eimeria tenella and eimeria necatrix |
| US4724145A (en) * | 1985-11-18 | 1988-02-09 | Merck & Co., Inc. | Eimeria acervulina immunogens |
| JPH0753669B2 (ja) * | 1985-11-25 | 1995-06-07 | 株式会社ゲン・コーポレーション | 鶏卵からの特異的抗体含有材料およびその製造方法と用途 |
| EP0225254B1 (en) * | 1985-11-25 | 1994-03-16 | Ghen Corporation | Specific antibody-containing substance from eggs and method of production and use thereof |
| JP2615673B2 (ja) * | 1987-10-05 | 1997-06-04 | 株式会社ゲン・コーポレーション | 食鳥の食中毒菌保菌抑制材料および食鳥肉の食中毒菌抑制方法 |
| ZA893740B (en) * | 1988-06-03 | 1990-02-28 | Hoffmann La Roche | Recombinant coccidiosis vaccines |
| JPH03151853A (ja) * | 1989-11-09 | 1991-06-28 | Kanebo Ltd | 抗体およびそれを有効成分とする整腸食品 |
| ZA9010461B (en) * | 1990-01-26 | 1991-10-30 | Hoffmann La Roche | Recombinant coccidiosis vaccines-5-7 eimeria surface antigen |
| EP0706400A1 (en) * | 1993-03-15 | 1996-04-17 | Pharma Pacific Pty. Ltd. | Therapeutic formulation and method |
| JP2738648B2 (ja) * | 1994-03-18 | 1998-04-08 | 中部飼料株式会社 | 抗コクシジウム症用飼料添加物,飼料,治療剤,予防方法,治療方法 |
| JPH0840935A (ja) * | 1994-07-27 | 1996-02-13 | Nisshin Flour Milling Co Ltd | 家禽類のコクシジウム症に対して免疫を付与する方法 |
| US5976580A (en) * | 1995-06-07 | 1999-11-02 | Novus International, Inc. | Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals |
| US5807551A (en) * | 1996-04-01 | 1998-09-15 | Iowa State University Research Foundation, Inc. | Method to provide artificial passive immunity in birds |
| EP1105153A4 (en) * | 1996-08-28 | 2005-01-19 | Ophidian Pharm Inc | POLYVALENT VACCINE AGAINST NEUROTOXIN (CLOSTRIDIUM BOTILINUM) |
| JPH10182483A (ja) * | 1996-12-26 | 1998-07-07 | Sumitomo Pharmaceut Co Ltd | コクシジウム抗原及びコクシジウム症ワクチン |
| US6019985A (en) * | 1998-02-27 | 2000-02-01 | Munova Corporation | Immunostimulation methods for providing disease protection in poultry |
| TWI348376B (en) * | 2002-02-26 | 2011-09-11 | Wyeth Corp | Selection of poultry eimeria strains through extra-intestinal sporozites |
| US8110188B2 (en) * | 2003-03-18 | 2012-02-07 | Investigacion Aplicada, S.A. De C.V. | Compositions for prevention and treatment of infections caused by coccidia in chickens |
-
2002
- 2002-06-28 JP JP2002189137A patent/JP3995541B2/ja not_active Expired - Fee Related
-
2003
- 2003-06-26 EP EP03736272A patent/EP1552848B1/en not_active Expired - Lifetime
- 2003-06-26 CN CNA03820567XA patent/CN1678349A/zh active Pending
- 2003-06-26 WO PCT/JP2003/008132 patent/WO2004002527A1/ja not_active Ceased
- 2003-06-26 AU AU2003243999A patent/AU2003243999A1/en not_active Abandoned
- 2003-06-26 AT AT03736272T patent/ATE411816T1/de not_active IP Right Cessation
- 2003-06-26 DE DE60324299T patent/DE60324299D1/de not_active Expired - Fee Related
- 2003-06-26 KR KR1020047021258A patent/KR100617415B1/ko not_active Expired - Fee Related
- 2003-06-26 US US10/519,536 patent/US20060057150A1/en not_active Abandoned
- 2003-06-27 TW TW092117674A patent/TW200410712A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE411816T1 (de) | 2008-11-15 |
| JP3995541B2 (ja) | 2007-10-24 |
| US20060057150A1 (en) | 2006-03-16 |
| EP1552848A4 (en) | 2006-02-08 |
| CN1678349A (zh) | 2005-10-05 |
| KR100617415B1 (ko) | 2006-08-30 |
| EP1552848A1 (en) | 2005-07-13 |
| KR20050024400A (ko) | 2005-03-10 |
| WO2004002527A1 (ja) | 2004-01-08 |
| DE60324299D1 (de) | 2008-12-04 |
| AU2003243999A1 (en) | 2004-01-19 |
| JP2004026775A (ja) | 2004-01-29 |
| EP1552848B1 (en) | 2008-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200410712A (en) | Anti-chicken coccidiosis composition | |
| Zhang et al. | Oral immunization with recombinant Lactobacillus casei expressing OmpAI confers protection against Aeromonas veronii challenge in common carp, Cyprinus carpio | |
| KR100426832B1 (ko) | 위염, 위궤양 및 십이지장궤양의 예방 또는 치료에 사용되는 특이적 항체 | |
| Immerseel et al. | Clostridium perfringens in poultry: an emerging threat for animal and public health | |
| Gharib et al. | Comparison of the effects of probiotic, organic acid and medicinal plant on Campylobacter jejuni challenged broiler chickens | |
| TWI459951B (zh) | 新穎噬菌體及含該噬菌體之抗菌組成物 | |
| US20250222101A1 (en) | Composition and Methods for Preventing and Treating African Swine Fever in Wild and Domestic Swine | |
| Duff et al. | Preliminary studies on development of a novel subunit vaccine targeting Clostridium perfringens mucolytic enzymes for the control of necrotic enteritis in broilers | |
| US20020009429A1 (en) | Pharmaceutical composition comprising a selected antigen and candida species antigen and methods | |
| Carter et al. | Control strategies for Salmonella colonization of poultry: The probiotic perspective | |
| KR100267747B1 (ko) | 돼지 대장균 및 유행성 설사바이러스에 의한 설사증 예방 및치료용 난황항체를 이용한 복합 면역제제 | |
| CN1594362A (zh) | 特异性抗幽门螺杆菌卵黄抗体、制备方法及其应用 | |
| Ferket et al. | Mannan oligosaccharides versus antibiotics for turkeys. | |
| AU696237B1 (en) | Prevention and treatment of enterohemorrhagic E.Coli infection | |
| KR20220167577A (ko) | FliC-FimA-CD40L 융합 항원을 발현하는 살모넬라 갈리나룸 변이주를 유효성분으로 포함하는 가금티푸스 및 살모넬라증 동시 예방 또는 치료용 백신 조성물 | |
| JP2004189672A (ja) | 抗下痢症組成物 | |
| JP2002529420A (ja) | 体重増加および食物効率を増加させるための組成物および方法 | |
| JPH08509211A (ja) | 菌、卵白及びにんにくの2種以上を含有する免疫賦活・感染防御剤 | |
| JP2022093735A (ja) | 細菌感染症用ダチョウ抗体 | |
| KR102873912B1 (ko) | 스트렙토코커스 파라우베리스 특이적 신규한 박테리오파지 jbf22001yu 및 이의 용도 | |
| WO2004105792A1 (ja) | 抗パルボウイルス感染症組成物 | |
| LACTOBACILLUS | CHAVAN NEHA GHANSHYAM | |
| CN1297315C (zh) | 抗仔猪细菌性疫病复合卵黄抗体制剂的制备方法 | |
| Cooper | Necrotic enteritis in broiler chickens: studies in disease reproduction and pathogenesis | |
| JP2010065010A (ja) | 胃炎、胃潰瘍および/または十二指腸潰瘍の予防および/または治療用組成物、ならびにそれを含有する飲食品 |